Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

stada arzneimittel ag - ksilometazolin - pršilo za nos, raztopina - ksilometazolin 0,87 mg / 1 ml - ksilometazolin

Evropska unija - slovenščina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaksel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - antineoplastična sredstva - prsi cancerdocetaxel v kombinaciji z doxorubicin in ciklofosfamid je primerna za adjuvant zdravljenje bolnikov z upravljajo node-pozitivnega raka dojk. docetaxel v kombinaciji z doxorubicin je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke, ki pred tem še niso prejele citotoksična terapija za to stanje. docetaxel monotherapy je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari citotoksična terapija. predhodna kemoterapija je morala vključevati antraciklin ali sredstvo za alkiliranje. docetaxel v kombinaciji z trastuzumab je indiciran za zdravljenje bolnikov z metastatskim rakom dojke, katerih tumorji, nad express her2 in ki predhodno še niso prejeli kemoterapijo za metastatskim bolezni. docetaxel v kombinaciji z capecitabine je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari citotoksična kemoterapija. predhodno zdravljenje bi moralo vključiti antraciklin. non-small cell lung cancerdocetaxel je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskim non-small cell lung cancer po izpadu pred kemoterapijo. docetaxel v kombinaciji z cisplatin je indiciran za zdravljenje bolnikov z unresectable, lokalno napredno ali metastatskim non-small cell lung cancer, pri bolnikih, ki pred tem še niso prejele kemoterapijo za to stanje. prostate cancerdocetaxel v kombinaciji z prednizon ali prednizolon je indiciran za zdravljenje bolnikov z hormon ognjevzdržni metastatskega raka prostate. Želodčni adenocarcinomadocetaxel v kombinaciji z cisplatin in 5-fluorouracil je indiciran za zdravljenje bolnikov z metastatskim želodca, adenokarcinom, vključno z adenokarcinom v gastroezofagealna križišču, ki ga še niso prejeli pred kemoterapijo za metastatskim bolezni. glave in vratu cancerdocetaxel v kombinaciji z cisplatin in 5-fluorouracil je primerna za indukcijsko zdravljenje bolnikov z lokalno napredno skvamoznih celic karcinom glave in vratu,.

Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za nadaljnje informacije o statusu receptorja človeškega epidermičnega rastnega faktorja 2 (her2) glejte poglavje 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. za nadaljnje informacije o statusu her2 glejte poglavje 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za nadaljnje informacije o statusu receptorja človeškega epidermičnega rastnega faktorja 2 (her2) glejte poglavje 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. za nadaljnje informacije o statusu her2 glejte poglavje 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - heparin - raztopina za injiciranje - heparin 5000 i.e. / 1 ml - heparin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - levofloksacin - raztopina za infundiranje - levofloksacin 5 mg / 1 ml - levofloksacin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - jabolčna kislina; kalcijev klorid dihidrat; magnezijev klorid heksahidrat; natrijev acetat trihidrat; natrijev klorid; kalijev klorid - raztopina za infundiranje - jabolčna kislina 0,67 g / 1000 ml  kalcijev klorid dihidrat0,37 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalcijev klorid dihidrat 0,37 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; magnezijev klorid heksahidrat 0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev acetat trihidrat 3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev klorid 6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml - elektroliti

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - jabolčna kislina; kalcijev klorid dihidrat; magnezijev klorid heksahidrat; natrijev acetat trihidrat; natrijev klorid; kalijev klorid - raztopina za infundiranje - jabolčna kislina 0,67 g / 1000 ml  kalcijev klorid dihidrat0,37 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalcijev klorid dihidrat 0,37 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; magnezijev klorid heksahidrat 0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev acetat trihidrat 3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev klorid 6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml - elektroliti

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - jabolčna kislina; kalcijev klorid dihidrat; magnezijev klorid heksahidrat; natrijev acetat trihidrat; natrijev klorid; kalijev klorid - raztopina za infundiranje - jabolčna kislina 0,67 g / 1000 ml  kalcijev klorid dihidrat0,37 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalcijev klorid dihidrat 0,37 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; magnezijev klorid heksahidrat 0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev acetat trihidrat 3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev klorid 6,8 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml - elektroliti

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun melsungen ag - jabolčna kislina; kalcijev klorid dihidrat; kalijev klorid; magnezijev klorid heksahidrat; natrijev acetat trihidrat; natrijev klorid - raztopina za infundiranje - jabolčna kislina 0,67 g / 1000 ml  kalcijev klorid dihidrat0,37 g / 1000 ml  kalijev klorid0,3 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml; kalcijev klorid dihidrat 0,37 g / 1000 ml  kalijev klorid0,3 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml  magnezijev klorid heksahidrat0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml; magnezijev klorid heksahidrat 0,2 g / 1000 ml  natrijev acetat trihidrat3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml; natrijev acetat trihidrat 3,27 g / 1000 ml  natrijev klorid6,8 g / 1000 ml; natrijev klorid 6,8 g / 1000 ml - elektroliti